热门资讯> 正文

Terns Pharmaceuticals GAAP每股收益为-0.27美元

2025-11-11 05:55

Terns Pharmaceuticals(TERN) 0
摩根士丹利(MS) 0

Terns Pharmaceuticals press release (TERN): Q3 GAAP EPS of -$0.27.
As of September 30, 2025, cash, cash equivalents and marketable securities were $295.6 million, as compared with $358.2 million as of December 31, 2024. Based on its current operating plan, Terns expects these funds will be sufficient to support its planned operating expenses into 2028

More on Terns Pharmaceuticals

Terns Pharmaceuticals: GLP-1 Obesity Drug Cut Warrants Downgrade To 'Hold' Rating
Terns Pharmaceuticals: Valued As If It Can't Win
Terns Pharmaceuticals, Inc. (TERN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Terns falls as phase 2 data on oral GLP-1 obesity asset disappoints
Seeking Alpha’s Quant Rating on Terns Pharmaceuticals

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。